Dhaliwal Harpreet S. sold $935K of PCVX
Dhaliwal Harpreet S. (Chief Technical Ops Officer) sold 17,000 shares of Vaxcyte, Inc. (PCVX) at $55.00 ($0.94M total) on 2026-08-05 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale size, price, and that it was executed under a pre-arranged Rule 10b5-1 plan; no other company-specific developments are provided.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 designation and lack of new fundamentals make it low-conviction for price action.
What to watch
The disclosure does not indicate whether the insider sold for diversification, tax planning, or routine liquidity; the 10b5-1 flag usually reduces interpretive weight.
Background
The article is an SEC Form 4 insider transaction report for Vaxcyte, Inc. (PCVX).
Ticker impact
Vaxcyte insider Dhaliwal Harpreet S., Chief Technical Ops Officer, sold 17,000 shares at $55.0040 on a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-only and typically fades quickly.
Form 4 shows an open-market sale under a pre-arranged Rule 10b5-1 plan, with no accompanying operational, financial, or regulatory catalyst described.
Market effects
No clear sector read-through because the filing is an individual 10b5-1 sale without new company guidance or trial/regulatory updates.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still be interpreted by some traders as confidence erosion, especially if paired with other negative signals not present here.
Key entities
- issuerVaxcyte, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderDhaliwal Harpreet S.
Chief Technical Ops Officer who sold shares.
- trading mechanismRule 10b5-1 plan
Pre-arranged plan noted as Yes, indicating the sale was scheduled in advance.
